Journal Logo

Research Article: Study Protocol Systematic Review

High-energy extracorporeal shock wave therapy for early stage femoral head osteonecrosis

A protocol of systematic review

Ji, Qing-hui MMa; Liu, Shi-chen MMa; Miao, Jie MMb; Ren, Zhi-xin MMb; Yuan, Yu-fei MMb; Li, Yan-bao MMb,∗

Author Information
doi: 10.1097/MD.0000000000021300
  • Open

Abstract

1 Introduction

Femoral head osteonecrosis (FHO) is common disorder in young adults, which can affect any joint but mostly attack hip joint.[1–4] It is characterized by decrease blood flow to the femoral head and thus results in cellular death, fractures, and collapse of joint surface.[5,6] Despite it is well-known, its pathology remains poorly understood, and it is difficult to diagnose at early stage, also known as early stage FHO (ESFHO).[7–9] Treatment approach of FHO depends on its stage, size, location, and its early diagnosis and preservation.[8,9] However, the efficacy is still unsatisfied.

High-energy extracorporeal shock wave therapy (HEEPSWT) is an invasive treatment approach that has been utilized for the treatment of numerous orthopedic disorders.[10–18] Several clinical trials have shown beneficial effects for patients with ESFHO.[10,19–26] However, there is not systematic review focusing on effectiveness and safety of HEEPSWT for ESFHO. Thus, the objective of this systematic review is to appraise the effectiveness and safety of HEEPSWT for patients with ESFHO.

2 Methods and analysis

2.1 Study registration

This protocol was registered on INPLASY202060055. It has been conducted according to the guideline of Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol statement guidelines.[27,28]

2.2 Eligibility criteria for study selection

2.2.1 Types of study

We will include all potential randomized controlled trials (RCTs) focusing on the effectiveness and safety of HEEPSWT for ESFHO in spite of language and publication status. We will exclude any other studies, such as animal studies, case report, case series, reviews, comments, non-clinical trials, non-controlled trials, and non-RCTs.

2.2.2 Types of participant

This study will fully consider patients who were clinically diagnosed as ESFHO for inclusion inconsiderate their country, race, sex, and age.

2.2.3 Types of intervention

In the experimental group, all subjects underwent single HEEPSWT intervention as their solely management.

In the control group, all patients received any treatments, but not any forms of HEEPSWT, will be included.

2.2.4 Types of outcome measurements

2.2.4.1 Primary outcome

Pain intensity of hip or knee joints (as assessed by Numerical Rating Scale or any other pain scales).

2.2.4.2 Secondary outcomes

Functional status and limitation of hip or knee joints (as evaluated by Western Ontario and McMaster Universities Osteoarthritis Index or other related indexes);

Health-related quality of life (as identified by 12-Item Short-Form Health Survey or other connected tools); and

Adverse events.

2.3 Literature search

We will identify the following electronic databases from conception to the present: Cochrane Library, EMBASE, PUBMED, Web of Science, Cumulative Index to Nursing and Allied Health Literature, VIP database, and China National Knowledge Infrastructure. No limitation will be applied to language and publication status. We will consider any potential RCTs that investigated the effectiveness and safety of HEEPSWT for ESFHO. The sample of search strategy for Cochrane Library is crated (Table 1). Similar search strategy with details will also be built for other electronic databases.

Table 1
Table 1:
Search strategy for Cochrane Library.

In addition, we will search dissertations, conference abstracts, and reference lists of any relevant reviews to avoid missing any potential literature.

2.4 Study selection

Two researchers will independently select all records using predefined eligibility criteria. It will be conducted by a pilot test to check inter-rater reliability and will correct each selecting step. At the first step, the tiles/abstracts of all searched citations will be scanned, and all unconnected records will be removed. At the second step, the remaining potential studies will be cautiously read through the full manuscripts against all inclusion criteria when necessary. Any divergences will be solved by discussion with the help of a third researcher. The whole procedure of study selection will be presented in a flow diagram.

2.5 Data extraction and management

Two independent researchers will extract data from each eligible trial using a predefined standardized data extraction form. The extracted data comprises of reference identification, author information, patient characteristics, study design, sample size, study methods, details of interventions and comparators, endpoints at different time points, results, findings, adverse events, conflict of interests, and funding information. Any disagreements will be figured out via discussion with the help of a third researcher.

2.6 Missing data dealing with

When there is insufficient or missing data, all corresponding or related authors of primary trials will be contacted to obtain it. If such data is not available, we will analyze the outcome data using an intention-to-treat analysis. We will also explore its potential affects in the discussion section.

2.7 Study quality assessment

Study quality of each included trial will be estimated based on the guidelines of Cochrane Risk of Bias Tool by 2 independent researchers. It comprises of 7 specific fields, and each one is further rated as low risk of bias, unclear risk of bias, and high risk of bias. Any differences in assessment will be resolved through consultation or discussion with the help of another researcher.

2.8 Statistical analysis

This study will utilize RevMan 5.3 software (Cochrane Community, London, UK) to perform statistical analysis.

2.8.1 Treatment effect measurement

Results regarding the pain intensity, functional status, limitation of knee or hip joints, and health-related quality of life, the outcome data will be expressed as mean difference, or standardized mean difference and 95% confidence intervals (CIs). Regarding the incidence of adverse events, it will be calculated as risk ratio and 95% CIs.

2.8.2 Heterogeneity assessment

The extent of statistical heterogeneity is investigated with I2 test. If I2 ≤ 50%, we will estimate it as having minor or low heterogeneity. If I2 > 50%, we will estimate it as having significant heterogeneity.

2.8.3 Data synthesis

If sufficient data will be collected with minor heterogeneity across the trials, we will undertake a meta-analysis according to the similar conditions of study and patient characteristics, specifics of interventions and controls, and outcome measurements. If we find significant heterogeneity across the studies, we will perform a subgroup analysis. If the meta-analysis is deemed not to be conducted, we will present outcome results as a narrative summary.

2.8.4 Subgroup analysis

We will perform subgroup analysis to identify any possible sources of substantial heterogeneity based on the variations in characteristics, different treatments, controls, outcome measurements.

2.8.5 Sensitivity analysis

We will conduct sensitivity analysis to examine the robustness of the merged outcomes by removing trials with low quality.

2.8.6 Publication bias

We will plan to run funnel plot and Egger test to detect if there are any reporting biases when we include at least 10 eligible trials.

2.8.7 Summary of evidence

The quality of evidence for main outcome will be assessed by the Grading of Recommendations Assessment, Development, and Evaluation System approach.[29,30] We will present its results in the “summary of findings” tables. If any conflicts occur, we will invite another researcher to solve them via discussion.

2.8.8 Dissemination and ethics

This study will not use individual patient data, thus no ethical approval is required. We will publish this study through a peer-reviewed journal.

3 Discussion

ESFHO is a frequency disorder in young adults.[1–4] Although it is a well-known condition, it is still not early to elaborate its pathology and diagnosis at early stage.[7–9] Previous clinical trials suggested HEEPSWT can effectively treat patients with ESFHO. However, their results are contradictory, and no systematic review explores this topic.

To the best of our knowledge, the results of this systematic review will fill a crucial knowledge gap of HEEPSWT for ESFHO. We hope the findings of this study will benefit both patients and clinicians. Additionally, this study may also help guide future research and relevant head-to head RCTs.

Author contributions

Conceptualization: Qing-hui Ji, Shi-chen Liu, Yu-fei Yuan, Yan-bao Li.

Data curation: Qing-hui Ji, Zhi-xin Ren, Yan-bao Li.

Formal analysis: Qing-hui Ji, Shi-chen Liu, Jie Miao, Yan-bao Li.

Investigation: Yan-bao Li.

Methodology: Qing-hui Ji, Jie Miao, Zhi-xin Ren, Yu-fei Yuan.

Project administration: Yan-bao Li.

Resources: Qing-hui Ji, Shi-chen Liu, Jie Miao, Zhi-xin Ren, Yu-fei Yuan.

Software: Qing-hui Ji, Shi-chen Liu, Jie Miao, Zhi-xin Ren, Yu-fei Yuan.

Supervision: Yan-bao Li.

Validation: Qing-hui Ji, Shi-chen Liu, Jie Miao, Yan-bao Li.

Visualization: Qing-hui Ji, Shi-chen Liu, Jie Miao, Zhi-xin Ren, Yu-fei Yuan, Yan-bao Li.

Writing – original draft: Qing-hui Ji, Shi-chen Liu, Zhi-xin Ren, Yu-fei Yuan, Yan-bao Li.

Writing – review & editing: Qing-hui Ji, Shi-chen Liu, Jie Miao, Zhi-xin Ren, Yu-fei Yuan, Yan-bao Li.

References

[1]. Fuchs B, Knothe U, Hertel R, et al. Femoral osteotomy and iliac graft vascularization for femoral head osteonecrosis. Clin Orthop Relat Res 2003;412:84–93.
[2]. Arlet J. Pathogenesis of non-traumatic femoral head osteonecrosis. Acta Orthop Belg 1999;65: (suppl): 25–9.
[3]. Delronge G, Lewalle J, Lemaire R, et al. Total prosthesis in avascular femoral head osteonecrosis. Acta Orthop Belg 1999;65: (suppl): 85–7.
[4]. Piat C. Aseptic femoral head osteonecrosis in the adult. Rev Prat 1998;48:356–60.
[5]. Mwale F, Wang H, Johnson AJ, et al. Abnormal vascular endothelial growth factor expression in mesenchymal stem cells from both osteonecrotic and osteoarthritic hips. Bull NYU Hosp Jt Dis 2011;69: (suppl): S56–61.
[6]. Ohzono K, Takaoka K, Saito S, et al. Intraosseous arterial architecture in nontraumatic avascular necrosis of the femoral head. Microangiographic and histologic study. Clin Orthop Relat Res 1992;277:79–88.
[7]. Lee MS, Hsieh PH, Shih CH, et al. Non-traumatic osteonecrosis of the femoral head - from clinical to bench. Chang Gung Med J 2010;33:351–60.
[8]. Sun W, Li Z, Shi Z, et al. Relationship between post-SARS osteonecrosis and PAI-1 4G/5G gene polymorphisms. Eur J Orthop Surg Traumatol 2014;24:525–9.
[9]. Kim SY, Kim YG, Kim PT, et al. Vascularized compared with nonvascularized fibular grafts for large osteonecrotic lesions of the femoral head. J Bone Joint Surg Am 2005;87:2012–8.
[10]. Xie K, Mao Y, Qu X, et al. High-energy extracorporeal shock wave therapy for nontraumatic osteonecrosis of the femoral head. J Orthop Surg Res 2018;13:25.
[11]. Bannuru RR, Flavin NE, Vaysbrot E, et al. High-energy extracorporeal shock-wave therapy for treating chronic calcific tendinitis of the shoulder: a systematic review. Ann Intern Med 2014;160:542–9.
[12]. Li ZY, Jin T, Shao ZW. Meta-analysis of high-energy extracorporeal shock wave therapy in recalcitrant plantar fasciitis. Swiss Med Wkly 2013;143:w13825.
[13]. Metzner G, Dohnalek C, Aigner E. High-energy Extracorporeal Shock-Wave Therapy (ESWT) for the treatment of chronic plantar fasciitis. Foot Ankle Int 2010;31:790–6.
[14]. Furia JP. High-energy extracorporeal shock wave therapy as a treatment for chronic noninsertional Achilles tendinopathy. Am J Sports Med 2008;36:502–8.
[15]. Albert JD, Meadeb J, Guggenbuhl P, et al. High-energy extracorporeal shock-wave therapy for calcifying tendinitis of the rotator cuff: a randomised trial. J Bone Joint Surg Br 2007;89:335–41.
[16]. Furia JP. High-energy extracorporeal shock wave therapy as a treatment for insertional Achilles tendinopathy. Am J Sports Med 2006;34:733–40.
[17]. Furia JP. The safety and efficacy of high energy extracorporeal shock wave therapy in active, moderately active, and sedentary patients with chronic plantar fasciitis. Orthopedics 2005;28:685–92.
[18]. Vogel J, Rompe JD, Hopf C, et al. High-energy extracorporeal shock-wave therapy (ESWT) in the treatment of pseudarthrosis. Z Orthop Ihre Grenzgeb 1997;135:145–9.
[19]. Zhang L, Cui Y, Liang D, et al. High-energy focused extracorporeal shock wave therapy for bone marrow edema syndrome of the hip: a retrospective study. Medicine (Baltimore) 2020;99:e19747.
[20]. Sun W, Li Z. Extracorporeal shockwave therapy for osteonecrosis of femoral head: traps and challenges. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2019;33:659–61.
[21]. Algarni AD, Al Moallem HM. Clinical and radiological outcomes of extracorporeal shock wave therapy in early-stage femoral head osteonecrosis. Adv Orthop 2018;2018:7410246.
[22]. Zhang Q, Liu L, Sun W, et al. Extracorporeal shockwave therapy in osteonecrosis of femoral head: a systematic review of now available clinical evidences. Medicine (Baltimore) 2017;96:e5897.
[23]. Ma YW, Jiang DL, Zhang D, et al. Radial extracorporeal shock wave therapy in a person with advanced osteonecrosis of the femoral head. Am J Phys Med Rehabil 2016;95:e133–9.
[24]. Gao F, Sun W, Li Z, et al. High-energy extracorporeal shock wave for early stage osteonecrosis of the femoral head: a single-center case series. Evid Based Complement Alternat Med 2015;2015:468090.
[25]. Ludwig J, Lauber S, Lauber HJ, et al. High-energy shock wave treatment of femoral head necrosis in adults. Clin Orthop Relat Res 2001;387:119–26.
[26]. Lauber S. High energy extracorporeal shockwave therapy in femur head necrosis. Z Orthop Ihre Grenzgeb 2000;138:3–4.
[27]. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
[28]. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.
[29]. Guyatt GH, Oxman AD, Vist GE, et al. Grade: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6.
[30]. Guyatt GH, Oxman AD, Schünemann HJ, et al. Grade guidelines: a new series of articles in the Journal of clinical epidemiology. J Clin Epidemiol 2011;64:380–2.
Keywords:

extracorporeal shock wave; femoral head; high-energy; osteonecrosis

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.